{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T15:12:57Z","timestamp":1769353977397,"version":"3.49.0"},"reference-count":73,"publisher":"Informa UK Limited","issue":"4","funder":[{"name":"Pfizer Biofarmac\u00eautica, Sociedade Unipessoal Lda"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines &amp; Immunotherapeutics"],"published-print":{"date-parts":[[2019,4,3]]},"DOI":"10.1080\/21645515.2018.1560769","type":"journal-article","created":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T18:55:40Z","timestamp":1547232940000},"page":"850-858","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal\n            <i>versus<\/i>\n            \u201cno vaccination\u201d and\n            <i>versus<\/i>\n            vaccination with the 23-valent pneumococcal polysaccharide vaccine"],"prefix":"10.1080","volume":"15","author":[{"given":"Miguel","family":"Gouveia","sequence":"first","affiliation":[{"name":"Cat\u00f3lica Lisbon School of Business and Economics, Universidade Cat\u00f3lica Portuguesa, Lisboa, Portugal"}]},{"given":"Gon\u00e7alo","family":"Jesus","sequence":"additional","affiliation":[{"name":"Centro de Estudos de Medicina Baseada na Evid\u00eancia, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal"}]},{"given":"M\u00f3nica","family":"In\u00eas","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, Pfizer Portugal, Porto Salvo, Portugal"}]},{"given":"Jo\u00e3o","family":"Costa","sequence":"additional","affiliation":[{"name":"Centro de Estudos de Medicina Baseada na Evid\u00eancia, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal"},{"name":"Laborat\u00f3rio de Farmacologia Cl\u00ednica e Terap\u00eautica, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal"},{"name":"Unidade de Farmacologia Cl\u00ednica, Instituto de Medicina Molecular, Lisboa, Portugal"}]},{"given":"Margarida","family":"Borges","sequence":"additional","affiliation":[{"name":"Centro de Estudos de Medicina Baseada na Evid\u00eancia, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal"},{"name":"Laborat\u00f3rio de Farmacologia Cl\u00ednica e Terap\u00eautica, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal"},{"name":"Unidade de Farmacologia Cl\u00ednica, Centro Hospitalar Lisboa Central EPE, Lisbon, Portugal"}]}],"member":"301","published-online":{"date-parts":[[2019,2,20]]},"reference":[{"key":"e_1_3_5_2_1","unstructured":"World Health Organization. Pneumococcal vaccines WHO position paper - 2012. Weekly epidemiological record No. 14. 2012; 87:129\u2013144."},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.05.030"},{"key":"e_1_3_5_4_1","unstructured":"World Health Organization. 23-valent pneumococcal polysaccharide vaccine WHO position paper. Weekly Epidemiological Record No. 42. 2008; 42:373\u2013384."},{"key":"e_1_3_5_5_1","volume-title":"Estat\u00edsticas da sa\u00fade 2013. Edi\u00e7\u00e3o 2015","author":"Instituto Nacional de Estat\u00edstica, I.P","unstructured":"Instituto Nacional de Estat\u00edstica, I.P. Estat\u00edsticas da sa\u00fade 2013. Edi\u00e7\u00e3o 2015. Lisboa, Portugal: Instituto Nacional de Estat\u00edstica, I.P.; 2015. [accessed 2016 Mar 1]. https:\/\/ine.pt."},{"key":"e_1_3_5_6_1","volume-title":"Doen\u00e7as respirat\u00f3rias em n\u00fameros - 2015","author":"Dire\u00e7\u00e3o-Geral da Sa\u00fade","unstructured":"Dire\u00e7\u00e3o-Geral da Sa\u00fade. Doen\u00e7as respirat\u00f3rias em n\u00fameros - 2015. Lisboa,\u00a0Portugal: Dire\u00e7\u00e3o-Geral da Sa\u00fade; 2016. [accessed 2016 Mar 1]. http:\/\/www2.portaldasaude.pt\/NR\/rdonlyres\/150AC37D-BEB4-4F9E-8FC4-4ECEEBB39B40\/0\/i022215.pdf."},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1553-7250(09)35058-8"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00083107"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e6879"},{"key":"e_1_3_5_10_1","unstructured":"Ara\u00fajo AT 10\u00ba Relat\u00f3rio Panorama das doen\u00e7as respirat\u00f3rias em Portugal Caminhos para o futuro. 2014\/2015. [accessed 2016 Mar 1]. http:\/\/www.ondr.pt\/10_Relatorio_ONDR.pdf."},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2000.04429.x"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.9.970"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.1997.00074.x"},{"key":"e_1_3_5_14_1","unstructured":"World Health Organization (WHO). Pneumococcal vaccines WHO position paper. Weekly Epidemiological Record No. 23. 1999; 74:177\u2013183."},{"key":"e_1_3_5_15_1","unstructured":"Summary of Product Characteristics of Prevenar 13. [accessed 2016 Mar 1]. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001104\/WC500057247.pdf."},{"key":"e_1_3_5_16_1","volume-title":"Programa Nacional de Vacina\u00e7\u00e3o. Introdu\u00e7\u00e3o da vacina conjugada de 13 val\u00eancias contra infe\u00e7\u00f5es por Streptococcus pneumoniae (Pn13). Norma n\u00ba 008\/2015 de 01\/06\/2015 atualizada a 05\/ 06\/2015","author":"Dire\u00e7\u00e3o-Geral da Sa\u00fade (DGS)","year":"2015","unstructured":"Dire\u00e7\u00e3o-Geral da Sa\u00fade (DGS). Programa Nacional de Vacina\u00e7\u00e3o. Introdu\u00e7\u00e3o da vacina conjugada de 13 val\u00eancias contra infe\u00e7\u00f5es por Streptococcus pneumoniae (Pn13). Norma n\u00ba 008\/2015 de 01\/06\/2015 atualizada a 05\/ 06\/2015. Lisboa,\u00a0Portugal: DGS; 2015."},{"key":"e_1_3_5_17_1","volume-title":"Vacina\u00e7\u00e3o contra infe\u00e7\u00f5es por Streptococcus pneumoniae de grupos com risco acrescido para doen\u00e7a invasiva pneumoc\u00f3cica (DIP). Idade pedi\u00e1trica (<18 anos de idade). Norma n\u00ba 012\/2015 de 23\/06\/2015 atualizada a 06\/ 11\/2015","author":"Dire\u00e7\u00e3o-Geral da Sa\u00fade (DGS)","year":"2015","unstructured":"Dire\u00e7\u00e3o-Geral da Sa\u00fade (DGS). Vacina\u00e7\u00e3o contra infe\u00e7\u00f5es por Streptococcus pneumoniae de grupos com risco acrescido para doen\u00e7a invasiva pneumoc\u00f3cica (DIP). Idade pedi\u00e1trica (<18 anos de idade). Norma n\u00ba 012\/2015 de 23\/06\/2015 atualizada a 06\/ 11\/2015. Lisboa,\u00a0Portugal: DGS; 2015."},{"key":"e_1_3_5_18_1","volume-title":"Vacina\u00e7\u00e3o contra infe\u00e7\u00f5es por Streptococcus pneumoniae de grupos com risco acrescido para doen\u00e7a invasiva pneumoc\u00f3cica (DIP). Adultos (\u226518 anos de idade). Norma n\u00ba 011\/2015 de 23\/06\/2015 atualizada a 06\/ 11\/2015","author":"Dire\u00e7\u00e3o-Geral da Sa\u00fade (DGS)","year":"2015","unstructured":"Dire\u00e7\u00e3o-Geral da Sa\u00fade (DGS). Vacina\u00e7\u00e3o contra infe\u00e7\u00f5es por Streptococcus pneumoniae de grupos com risco acrescido para doen\u00e7a invasiva pneumoc\u00f3cica (DIP). Adultos (\u226518 anos de idade). Norma n\u00ba 011\/2015 de 23\/06\/2015 atualizada a 06\/ 11\/2015. Lisboa,\u00a0Portugal: DGS; 2015."},{"key":"e_1_3_5_19_1","first-page":"S13","article-title":"The cost and burden of schizophrenia in Portugal in 2015","volume":"4","author":"Gouveia M","year":"2017","unstructured":"Gouveia M, Ascen\u00e7\u00e3o R, Fiorentino F, Pascoal J, Costa J, Borges M. The cost and burden of schizophrenia in Portugal in 2015. Int J Clin Neurosci Ment Health. 2017;4:S13.","journal-title":"Int J Clin Neurosci Ment Health"},{"key":"e_1_3_5_20_1","volume-title":"Vacina\u00e7\u00e3o antigripal da popula\u00e7\u00e3o portuguesa na \u00e9poca 2015\/2016. Estudo na amostra ECOS","author":"Instituto Nacional de Sa\u00fade Doutor Ricardo Jorge (INSA, IP)","year":"2016","unstructured":"Instituto Nacional de Sa\u00fade Doutor Ricardo Jorge (INSA, IP). Vacina\u00e7\u00e3o antigripal da popula\u00e7\u00e3o portuguesa na \u00e9poca 2015\/2016. Estudo na amostra ECOS. Lisboa,\u00a0Portugal: Instituto Nacional de Sa\u00fade Doutor Ricardo Jorge (INSA, IP); 2016."},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408544"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200003000-00003"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000027926.99356.4c"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-3422"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0903029"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy312"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1411196"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199111213252101"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/003335491613100306"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2006.10.018"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2018.02.007"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.05.076"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.23268"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19991215)18:23<3263::AID-SIM315>3.0.CO;2-3"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.01.007"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/2191-1991-2-4"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/jep.12131"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.06.017"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.169"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1586\/erp.12.55"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1428507"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0149540"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0192640"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00325-2015"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197905"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.03.003"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-015-0345-z"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00103-016-2466-9"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199427"},{"key":"e_1_3_5_50_1","unstructured":"Silva EA Pinto CG Sampaio C Pereira J Drummond M Trindade R Orienta\u00e7\u00f5es Metodol\u00f3gicas para Estudos de Avalia\u00e7\u00e3o Econ\u00f3mica de Medicamentos. INFARMED; 1998 Nov."},{"key":"e_1_3_5_51_1","volume-title":"Popula\u00e7\u00e3o residente (N.\u00ba) por Local de resid\u00eancia (NUTS - 2013), Sexo e Grupo et\u00e1rio","author":"Instituto Nacional de Estat\u00edstica (PNSI)","year":"2015","unstructured":"Instituto Nacional de Estat\u00edstica (PNSI). Popula\u00e7\u00e3o residente (N.\u00ba) por Local de resid\u00eancia (NUTS - 2013), Sexo e Grupo et\u00e1rio. Anual. Lisboa,\u00a0Portugal: Instituto Nacional de Estat\u00edstica; 2015. [accessed 2016 Mar 1]. https:\/\/www.ine.pt."},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1086\/431521"},{"key":"e_1_3_5_53_1","unstructured":"Instituto Nacional de Estat\u00edstica (PNSI) e Instituto Nacional de Sa\u00fade Doutor Ricardo Jorge (INSA). Inqu\u00e9rito Nacional de Sa\u00fade (INS) 2005\/2006 [microdados]."},{"key":"e_1_3_5_54_1","volume-title":"Infe\u00e7\u00e3o VIH\/SIDA: a situa\u00e7\u00e3o em Portugal a 31 de dezembro de 2012","author":"Instituto Nacional de Sa\u00fade Doutor Ricardo Jorge (INSA, IP)","year":"2013","unstructured":"Instituto Nacional de Sa\u00fade Doutor Ricardo Jorge (INSA, IP). Infe\u00e7\u00e3o VIH\/SIDA: a situa\u00e7\u00e3o em Portugal a 31 de dezembro de 2012. Lisboa,\u00a0Portugal: Instituto Nacional de Sa\u00fade Doutor Ricardo Jorge (INSA, IP); 2013."},{"key":"e_1_3_5_55_1","volume-title":"Infe\u00e7\u00e3o VIH\/SIDA: a situa\u00e7\u00e3o em Portugal a 31 de dezembro de 2013","author":"Instituto Nacional de Sa\u00fade Doutor Ricardo Jorge (INSA, IP)","year":"2014","unstructured":"Instituto Nacional de Sa\u00fade Doutor Ricardo Jorge (INSA, IP). Infe\u00e7\u00e3o VIH\/SIDA: a situa\u00e7\u00e3o em Portugal a 31 de dezembro de 2013. Lisboa,\u00a0Portugal: Instituto Nacional de Sa\u00fade Doutor Ricardo Jorge (INSA, IP); 2014."},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073704"},{"key":"e_1_3_5_57_1","unstructured":"Administra\u00e7\u00e3o Central do Sistema de Sa\u00fade ACSS I.P. 2014 [microdados]."},{"key":"e_1_3_5_58_1","unstructured":"Data on file Wyeth Research 2006."},{"key":"e_1_3_5_59_1","volume-title":"T\u00e1bua Completa de Mortalidade para Portugal - 2011-2013","author":"Instituto Nacional de Estat\u00edstica (PNSI)","unstructured":"Instituto Nacional de Estat\u00edstica (PNSI). T\u00e1bua Completa de Mortalidade para Portugal - 2011-2013. Lisboa,\u00a0Portugal: Instituto Nacional de Estat\u00edstica; [accessed 2016 Mar 1]. https:\/\/www.ine.pt."},{"key":"e_1_3_5_60_1","unstructured":"Instituto Nacional de Estat\u00edstica (PNSI). \u00d3bitos (N.\u00ba) por Local de resid\u00eancia (NUTS - 2013) Sexo Grupo et\u00e1rio e Causa de morte (Lista OCDE adaptada); Anual 2013. [accessed 2016 Mar 1]. https:\/\/www.ine.pt."},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-12-200306170-00007"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:EJEP.0000024701.94769.98"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.10.024"},{"key":"e_1_3_5_64_1","first-page":"CD000422","article-title":"Vaccines for preventing pneumococcal infection in adults","volume":"23","author":"Moberley SA","year":"2008","unstructured":"Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2008;23:CD000422.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2012.11.035"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-007-0327-z"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.18.1938"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(02)00451-6"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00003814"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70090-1"},{"key":"e_1_3_5_71_1","unstructured":"Pfizer Lda. Data on file 2016."},{"key":"e_1_3_5_72_1","unstructured":"Public Health England. Quarterly vaccine coverage data tables. [accessed 2016 Mar 1]. https:\/\/www.gov.uk\/government\/publications\/pneumococcal-polysaccharide-vaccine-ppv-vaccine-coverage-estimates."},{"key":"e_1_3_5_74_1","unstructured":"INFARMED. INFOMED - base de dados de medicamentos de uso humano. [accessed 2016 Mar 1]. http:\/\/app7.infarmed.pt\/infomed\/inicio.php."},{"key":"e_1_3_5_75_1","volume-title":"Boletim Estat\u00edstico - Maio de 2015","author":"Gabinete de Estrat\u00e9gia e Estudos (GEE)","unstructured":"Gabinete de Estrat\u00e9gia e Estudos (GEE). Boletim Estat\u00edstico - Maio de 2015. Lisboa,\u00a0Portugal: Minist\u00e9rio da Economia, Gabinete de Estrat\u00e9gia e Estudos (GEE); [accessed 2016 Mar 1]. http:\/\/www.gee.min-economia.pt."}],"container-title":["Human Vaccines &amp; Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2018.1560769","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T07:43:56Z","timestamp":1707896636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2018.1560769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,20]]},"references-count":73,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4,3]]}},"alternative-id":["10.1080\/21645515.2018.1560769"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2018.1560769","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-07-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}